NASDAQ Healthcare Biotechnology HRMY

Harmony Biosciences Holdings, Inc.

$ 33.28 -1.45 %

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

CEO: Jeffrey Dayno - https://www.harmonybiosciences.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

$43 29.21 %

Recommandation

Buy

DCF

$ 115.91

Loading data...

HRMY vs S&P500

Loading data...

No data available.

Quick ratio

3.56

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

13.42

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

2.48

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

17.19 %

reflects reasonable profitability, showing good use of equity.

ROIC

12.50 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

8.40

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.23

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

5.91

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
5 indicates moderate financial health
Altman score
5.19 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
2.71 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.16 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.